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Summary
Podocytes maintain the structure and function of the glomerular filtration
barrier. However, podocytes have recently been implicated in the innate
immune response, and their function as non-haematopoietic antigenpresenting cells was highlighted. We have shown previously that excessive
expression of the chemokine CXCL13 is a distinctive early event for nephritis
in a murine model of systemic lupus erythematosus (SLE). Furthermore, we
found that CXCL13 is elevated significantly in the serum of patients with
SLE-nephritis. In this study, we were able to show for the first time that (i)
CXCL13 is expressed locally in glomeruli in a model for SLE-nephritis in
mice and that (ii) incubation of human podocytes with CXCL13 induces
receptor stimulation of CXCR5 with activation of signalling pathways,
resulting in (iii) secretion of proinflammatory cytokines and chemokines in
culture supernatant. This cytokine/chemokine cocktail can lead to (iv) a
neutrophil respiratory burst in isolated human granulocytes. Taken together,
our results provide further evidence that CXCL13 is involved in the pathogenesis of glomerulonephritis and that podocytes can play an active role in
local proinflammatory immune responses. Thus, CXCL13 could be a direct
target for the therapy of glomerulonephritis in general and for SLE-nephritis
in particular.
Keywords: CXCL13, chemokines, podocytes, proinflammatory signaling,

SLE-nephritis

Introduction
Inflammation is one of the leading reasons for the development of glomerulonephritis, a major cause of progressive
kidney disease [1]. The innate immune response is an old
evolutionarily conserved non-specific defence system protecting the organism against infections. One of the major
events occurring during an innate immune response is the
recruitment of immune cells towards the site of required
action via secretion of cytokines and chemokines. This leads
to the removal of apoptotic cells and regeneration or wound
healing [2]. The balance between a protective immune
response and an autoimmune reaction, where body cells are
recognised as foreign, is very critical. There are many examples where infections and inflammation are described as a
responsible trigger for autoimmunity [3]. In this context,
cross-reactivity between pathogen-derived and self-derived
antigens plays an important role (for review see [4]). The
chemokine CXC ligand 13 protein (CXCL13), also known
20

as B cell-attracting chemokine-1 (BAC-1) or B lymphocyte
chemoattractant (BLC), is a CXC subtype member of the
chemokine superfamily [5]. CXCL13 is particularly important in the context of autoimmunity, as it has been demonstrated that CXCL13 is sufficient to induce secondary
lymphoid tissues in peripheral organs. Via its receptor
CXCR5, expressed on follicular dendritic cells and follicular
T helper cells (Tfh), CXCL13 is crucial for germinal centre
formation [6,7]. We and others have linked CXCL13 expression to the onset of nephritis in a mouse model for SLEnephritis [8,9]. Of note, in the expression profile of 61
inflammatory molecules, CXCL13 was one of only a few
markers that were elevated at a very early point of disease,
suggesting a possible role of this chemokine for disease
manifestation [10]. Furthermore, we and others found that
CXCL13 is elevated in the serum of patients with SLEnephritis [11–15]. This is of interest, as lupus nephritis
belongs to the most severe complications of SLE, with
unsatisfactory treatment strategies with respect to remission
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induction and unwanted toxic effects (for a review,
see [16]).
In the kidneys, the major cell type secreting CXCL13 was
identified as non-resident dendritic cells [9,10,17,18].
Podocytes, which are the epithelial cells at the kidney filtration barrier, have been linked to the innate immune
response and are known to express several chemokine
receptors [19,20]. Recently, it was published that intrinsic
proinflammatory signalling in podocytes contributes to
podocyte damage and aggravated proteinuria in experimental glomerulonephritis in mice, indicating that production
and secretion of proinflammatory chemokines by
podocytes has a physiological role in this setting [21].
To our knowledge, we are the first to show that CXCL13
is expressed in the glomerula of a mouse model of SLEnephritis and that CXCL13 acts directly on human
podocytes. We are able to demonstrate that cultured human
podocytes in vitro express the CXCL13 receptor CXCR5 and
are responsive to even low concentrations of recombinant
CXCL13 (500 pg/ml). This concentration corresponds to
the concentration detected in the serum of patients with
active, severe SLE-nephritis class IV. In addition, we show
that stimulation of human cultured podocytes with
CXCL13 results in a proinflammatory and chemoattractant
signature. Furthermore, podocyte response to CXCL13
induces a respiratory burst in isolated human neutrophilic
granulocytes. Collectively, our results suggest that CXCL13/
CXCR5 signalling in podocytes can induce a
proinflammatory milieu which could influence the development of leucocyte infiltration observed in severe (classes III
and IV) lupus nephritis.

Materials and methods
Human podocyte culture
For this study, immortalised human podocytes (gift from
Moin Saleem, University of Bristol, UK) were cultured as
described previously [22]. The cells contain the tsSV40 T
gene and are in a proliferative state when cultured in RPMI1640 medium containing 10% fetal calf serum (FCS) and 1%
penicillin/streptomycin at 33°C. Expression of the podocyte
marker proteins WT-1 and synaptopodin was confirmed
after 14 days of differentiation by thermoswitching to 37°C.
For stimulation experiments, human podocytes were serumstarved in 1% FCS overnight.

bated with the primary CXCL13 polyclonal rat anti-mouse
antibody (1:50; Biorbyt, San Francisco, CA, USA) or CD11c
monoclonal hamster anti-mouse antibody (1:200; BD
Pharmingen, Erembodegem, Belgium) for 1 h in a humid
chamber at room temperature. For fluorescent visualisation
of bound primary antibodies, sections were further incubated with Alexa Fluor 555 goat anti-rat immunoglobulin
(Ig)G conjugated secondary antibody (Invitrogen, Carlsbad,
CA, USA) for 1 h. Sections were analysed using a Leica
imaging microscope by an investigator blinded for the
animal group assignment. The semiquantitative scoring of
glomerular expression was: 0 = no expression, 1 = mild
expression < 20% of glomeruli stained, 2 = 21–50% of glomeruli stained, 3 = 50–75% of glomeruli stained and
4 = extensive glomerular staining of > 75% of glomeruli.

Western blot analysis
Whole cell protein lysates were harvested from differentiated cultured human podocytes, which were either left
untreated or treated with 500 pg/ml recombinant human
CXCL13 (R&D Systems, Wiesbaden, Germany) for the
indicated time-points. Cells were lyzed on ice in
radioimmunoprecipitation assay (RIPA) buffer [50 mM
Tris, pH 7·5, 150 mM NaCl, 0·5% sodium deoxycholate, 1%
Nonidet P-40, 0·1% sodium dodecyl sulphate (SDS)]
containing protease inhibitors (complete mini; Roche,
Mannheim, Germany), 1 mM sodium orthovanadate,
50 mM NaF and 200 μg/l okadaic acid. Lysates were
centrifuged for 15 min at 12 000 g, and aliquots of the
supernatants were separated by 10% sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred to polyvinylidene difluoride membranes
(Immobilon-P; Millipore, Bedford, MA, USA). After
probing with primary antibodies [mouse anti-p-p44/42
mitogen-activated protein kinase (MAPK) (phosphoextracellular-regulated kinase – ERK) or rabbit anti-p44/42
MAPK (total ERK1/2) (Cell Signaling Technology, Santa
Cruz, CA, USA)], antigen–antibody complexes were
detected with horseradish peroxidase-labelled anti-rabbit
and anti-mouse secondary antibodies (Santa Cruz
Biotechnologies, Santa Cruz, CA, USA), respectively, and
visualised using SuperSignal® West Pico Chemiluminescent
Substrate (Pierce, Rockford, IL, USA), according to the
manufacturer’s protocol.

Immunohistochemistry

Fluorescence activated cell sorter (FACS) analysis

Snap-frozen renal cryosections from New Zealand Black/
White F1 mice with lupus nephritis and controls were used
for immunohistochemistry. For indirect immunofluorescence, non-specific binding sites were blocked with 10%
normal donkey serum (Jackson ImmunoResearch, West
Grove, PA, USA) for 30 min. Thereafter, sections were incu-

Flow cytometry was performed on a FACSCanto I (BD
Biosciences, San Jose, CA, USA) with FACSDiva software
version 6·0. Data were analysed using WinListTM software
(Verity Software House, Topsham, ME, USA). Differentiated
human podocytes were trypsinised and stained with an
anti-human CXCR5 (R&D Systems) or an isotype matched
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control antibody followed by a fluorescein isothiocyanate
(FITC)-labelled secondary antibody.

Multiplex analysis
Cell culture supernatants of human podocytes were harvested before and after stimulation with 500 pg/ml CXCL13
for 8 and 24 h. Unstimulated cell culture supernatants were
harvested at matching time-points. Cytokine and
chemokine content were analysed using the Luminex-based
multiplex technique, according to the manufacturer’s
instructions (BioPlex assay, Bio-Rad, Hercules, CA, USA).
In brief, 50 μl of culture supernatant and lyophilised
cytokine and chemokine standard were incubated at room
temperature (RT) for 30 min with a bead mixture coated
with the antibodies for the respective cytokine or
chemokine. Serial dilution series (1:4) were performed to
generate standard curves for each protein. After three wash
steps with 100 μl wash buffer, the mixture of secondary
biotinylated antibodies was added for 30 min at RT,
followed by three wash steps. Finally, streptavidin–
phycoerythrin (SA–PE) was added for 10 min at RT (1:100
dilution) in order to detect the amount of bound secondary
monoclonal antibody that correlated with the cytokine or
chemokine concentration. After three final washing steps,
the beads were resuspended in 125 μl assay buffer and
acquired and analysed using the BioPlex Manager version
6·0 software that calculates standard curves using a fiveparameter logistic plot formula, which allows the calculation of protein concentrations in the samples (pg/ml).
Three independent experiments were analysed and each
supernatant and each time-point was measured in duplicate
on the multiplex protein array. Statistical analysis was performed by Student’s t-test.

Preparation of human neutrophilic granulocytes
Peripheral venous blood was drawn from healthy volunteers
after local ethics board approval (MHH 2010/807) and
informed consent. Neutrophilic granulocytes were isolated
by density gradient centrifugation, as described previously
[23].

Measurement of respiratory burst by oxidation of
dihydrorhodamine (DHR) to rhodamine
Isolated neutrophilic granulocytes were cultured at a concentration of 5 × 106 cells/ml for 24 h in podocyte supernatants
recovered 8 h after stimulation with/without CXCL13. Cells
were loaded with DHR (1 μM) for 10 min at 37°C followed
by stimulation with recombinant human tumour (AE)
necrosis factor (TNF)-alpha (20 ng/ml; Peprotech, Rocky
Hill, NJ, USA) for 20 min. Mean fluorescence intensity was
assessed by flow cytometry on a BD FACSCanto I (Becton
Dickinson, Heidelberg, Germany), and data were analysed
22

using FlowJo software (TreeStar Inc., Ashland, OR, USA).
Mean fluorescence intensity (MFI, after correction for baseline) of cells cultured in medium of stimulated podocytes
was compared to medium from unstimulated podocyte controls harvested at the same time-point and incubated with
neutrophils from the same donor. Seven incubation experiments in isolated neutrophilic granulocytes were performed
using cell culture supernatants from four independent
podocyte stimulation experiments. Results are expressed as
foldness of control MFI, as baseline levels varied in different
donors. Values from control versus CXCL13-stimulated
groups were compared by Mann–Whitney U-test; P < 0·05
was considered significant and is indicated by *.

Results
Dendritic cells and local production of CXCL13 are
detectable in glomeruli of nephritic NZB/W-F1 mice
We have published previously that CXCL13 is expressed in
inflammatory infiltrates of nephritic NZB/W F1 mice [9].
Here we evaluated the local expression of CXCL13 in the glomeruli of nephritic mice by staining a set of nephritic SLE
mice and non-nephritic control mice for CXCL13 and for the
dendritic cell marker CD11c. We observed glomerular infiltration with dendritic cells and glomerular expression of
CXCL13 protein in the majority of nephritic glomeruli
(Fig. 1a–h). At the mRNA level we found a significant
increase of CXCL13 expression in nephritic mice versus controls (Fig. 1i). Next, we wanted to address the question
whether CXCL13, which is known to be expressed at the
mRNA level long before the onset of lupus nephritis [11], has
a potential influence on the disease process in lupus nephritis
by triggering an intrinsic cell response in podocytes.

Immortalised human podocytes in culture express
CXCR5 that is responsive to CXCL13 stimulation
Expression of CXCR5 and other chemokine receptors in
primary cultured podocytes has been described previously
based on mRNA expression analysis [20]. In the present
work, we asked whether an immortalised human podocyte
cell line in culture expresses a functional form of the receptor CXCR5 and if stimulation with CXCL13 can induce a
specific signalling response in podocytes. To accomplish
this, we first analysed the expression of CXCR5 on differentiated immortalised human podocytes by flow cytometry.
As shown in Fig. 2a, roughly 20% of the cultured podocytes
expressed CXCR5 on their surface. Next, we analysed the
ERK1/2 phosphorylation response in podocytes as a classical downstream mediator of chemokine receptor activation
[24]. For stimulation of podocytes, we chose 500 pg/ml
CXCL13, as this corresponds to the medium serum concentration that we detected in highly active SLE patients [SLE
Disease Activity Index (SLEDAI) > 8] in our Hannover
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Fig. 2. Functional CXCR5 is expressed on
human podocytes in vitro. (a) Cell surface
expression of CXCR5 on cultured human
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activated cell sorter (FACS) analysis.
Differentiated human podocytes were stained
with CXCR5 or an isotype control antibody
followed by fluorescein isothiocyanate
(FITC)-labelled secondary antibody. (b)
Stimulation of differentiated human podocytes
with recombinant human CXCL13 induces an
extracellular-regulated kinase (ERK)1/2 (42/44)
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(red fluorescence;
4′,6-diamidino-2-phenylindole (DAPI) for
nuclear counterstaining). While CD11c and
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CXCL13 induces secretion of a variety of
proinflammatory factors in human podocytes
Next, we performed multiplex protein arrays from cell
culture supernatants of three independent experiments from
human podocytes that were stimulated for 8 h and 24 h with
CXCL13 in comparison to untreated controls to evaluate if
stimulation with 500 pg/ml of recombinant CXCL13 could
induce specific secretion of other proinflammatory cytokines
and chemokines. One of the most significantly up-regulated
factors in the culture supernatant was CXCL1 (Gro-α)
(Fig. 3a). This chemokine is known for its ability to attract
neutrophils to sites of inflammation [25,26]. Further experiments showed an up-regulation of CXCL12 (SDF-1α) secretion following stimulation (Fig. 3b). CXCL12 is a chemokine
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Fig. 3. CXCL13 stimulation induces production
of proinflammatory mediators in human
podocytes. Differentiated podocytes were
stimulated with 500 pg/ml of recombinant
CXCL13 for the time-points indicated. Culture
supernatants were harvested and analysed for
cytokine and chemokine content using
Multiplex analysis. Significantly up-regulated
factors detectable in the culture supernatant
include: (a) CXCL1 (*P < 0·001), (b) CXCL12
(**P < 0·001/*P < 0·003), (c) macrophage
migration inhibitory factor (MIF) (**P < 0·01;
*P < 0·05), (d) leukaemia inhibiting factor (LIF)
(*P < 0·03; *P < 0·05), (e) intercellular adhesion
molecule 1 (ICAM-1) (**P < 0·001; *P < 0·03)
and (f) vascular cell adhesion protein 1
(VCAM-1) (**P < 0·01; *P < 0·05) (three
independent experiments).
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24
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that is highly efficient in inducing chemotaxis of lymphocytes and macrophages [27,28]. We also found a significant
up-regulation of macrophage migration inhibitory factor
(MIF) (Fig. 3c), a proinflammatory cytokine normally
secreted by white blood cells in response to bacterial antigens
as well as leukaemia inhibitory factor (LIF) (Fig. 3d), a
pleiotropic glycoprotein of the IL-6 family that has been
shown to protect podocytes against oxidative stress [29]. Furthermore, we detected soluble intercellular adhesion molecule 1 (ICAM-1) and vascular adhesion molecule 1
(VCAM-1) (Fig. 3e,f) in the culture supernatants. Both adhesion molecules are expressed in the inflammatory milieu and
also indicate a more migratory phenotype of podocytes,
which has been described previously as a key step in crescent
formation in glomerulonephritis [30].
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Fig. 4. Podocyte supernatant after exposure to CXCL13 increases
neutrophil respiratory burst. Neutrophil respiratory burst in response
to tumour necrosis factor (TNF)-alpha was assessed after 24 h in
control (ctrl) and CXCL13-treated podocyte supernatants (seven
neutrophil exposure experiments, **P = 0·02).

CXCL13 stimulated podocytes can induce respiratory
burst in human neutrophils
We tested the respiratory burst activity of isolated human
neutrophils after pre-incubation with cell culture supernatants of podocytes stimulated with 500 pg/ml CXCL13 for
8 h. The isolated neutrophils were cultured at a concentration of 5 × 106/ml for 24 h in freshly recovered podocyte
supernatants. After loading the cells with DHR, cells were
stimulated with recombinant human TNF-α (20 ng/ml) for
20 min. DHR is reduced to rhodamine in the presence of
reactive oxygen species (ROS). When we compared the fluorescence intensity of cells by flow cytometry, we discovered
a significantly enhanced respiratory burst in neutrophils
that were pre-incubated with culture supernatants of
podocytes after CXCL13 stimulation, indicating a
proinflammatory milieu of the culture medium (Fig. 4).

Discussion
In SLE patients, circulating CXCL13 can function as a
marker of disease activity and B cell activation and is
elevated significantly in patients with lupus nephritis [11–
14]. However, the relevance of CXCL13 in the process of the
development of lupus nephritis has so far remained elusive.
Podocytes are highly specialised glomerular epithelial
cells that play a key role for kidney function [31]. Different
studies have proved over the last decades that podocyte
damage initiates progression of many glomerular diseases
that can lead to proteinuria and chronic kidney failure. The
role of podocytes in disease progression is manifold: one
major reason is a destabilisation of the glomerular filtration
barrier due to podocyte alterations [32,33]. Recently, a new

role of podocytes has been highlighted. There is growing
evidence that podocytes also play a relevant role in immunological reactions. Reiser et al. were able to show for the
first time that, under pathological conditions, podocytes
up-regulate B7-1 (CD80), a molecule that was known to be
expressed mainly by antigen-presenting cells (APC) and to
induce T cell co-stimulation [34,35]. Despite this, podocyte
structures can function as antigens, as shown with different
podocyte autoantibodies in membranous nephropathy
[36,37]. Interestingly, it has been published recently that
treatment of patients with B7-1-positive glomerular diseases by a co-stimulatory inhibitor that targets B7-1 (CD80)
induces partial or complete remission of proteinuria [24].
In view of this speculated new function of podocytes, and
our knowledge that the chemokine CXCL13 is elevated significantly on protein level in serum of patients with lupus
nephritis [11], we aimed to study whether or not CXCL13
can modulate podocyte function and induce an immunological response in these cells.
Here we were able to show for the first time, using
immunohistological studies, that there is local expression of
CXCL13 in the glomeruli of nephritic mice. As Ishikawa
et al. previously described dendritic cells as the major
source of CXCL13 production [17], we stained glomeruli
with a dendritic cell marker, and we indeed detected a significant amount of infiltrating CD11c-positive cells in the
glomeruli of nephritic animals. Well in line with our previous studies, we also detected strong expression of CXCL13
in CD11c containing perivascular infiltrates in nephritic
NZB/W F1 mice (data not shown) [9].
Using FACS analysis, we were able to confirm that differentiated human podocytes in cell culture express CXCR5,
the receptor of CXCL13. To prove that incubation of differentiated human podocytes with CXCL13 leads to a CXCR5mediated signalling event in these cells, we measured the
ERK phosphorylation response in podocytes after CXCL13
stimulation. ERK phosphorylation is a classical downstream
mediator of chemokine receptors [38]. As expected,
CXCL13 induced a strong ERK phosphorylation response
over time, indicating responsiveness of podocytes to
chemokine stimulation. This is well in line with a previously
published study on ERK signalling in response to CXCL13
in other epithelial cells [39].
In immune cells, CXCL13 stimulation leads to a release of
cytokines and an enhancement of the immunological
signal. To assess whether podocytes can act similarly, we
analysed the culture supernatants of podocytes after stimulation with CXCL13 for cytokine and chemokine content.
This is of special interest, as glomerular-produced
chemokines are not only necessary for recruitment of nonresident inflammatory cells, but are known to alter functions of resident glomerular cells, such as the formation of
extracellular matrix, ROS production and apoptosis [40]. In
our study, several chemokines and cytokines were secreted
in the supernatant of stimulated podocytes. Of interest, we
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found two chemokines, CXCL1 and CXCL12, that are both
highly efficient for the recruitment of neutrophils and lymphocytes, a classical feature of lupus nephritis classes III and
IV [25–28]. Even though the expression of CXCL1 by
podocytes has not been described previously, CXCL1 and
CXCL12 have been mentioned in the context of different
glomerular diseases [41,42]. In our multiplex cytokine array
experiments we also detected significant expression of the
proinflammatory cytokines MIF and LIF and of the adhesion molecules ICAM-1 and VCAM-1. MIF and LIF are
known to be increased in kidney diseases, and blockade of
MIF or its receptor protects from experimental kidney
injury [43]. Well in line with our data, the expression of
ICAM-1 by podocytes has been described previously in
kidney sections of mice after induction of experimental
crescentic glomerulonephritis [30]. Despite this, ICAM-1
and VCAM-1 secretion by podocytes could result in the
retention of lymphocytes, macrophages and neutrophils in
the kidney supporting local immune reactions.
It is of note that ICAM-1 and VCAM-1 are required for
the retention and clustering of lymphoid tissue inducer cells
(CD3–CD4+CD45+ cells) and other haematopoietic cells at
the sites of lymphoid organogenesis and neogenesis [44].
Therefore, it is tempting to speculate that secretion of
ICAM-1 and VCAM-1 by podocytes due to the CXCL13 signalling response could also be a relevant event contributing
to the migration of inflammatory cells into the kidney. In
addition, we demonstrate that the chemokine/cytokine mix
secreted by podocytes has a functional role. We found that
culture supernatants from CXCL13-stimulated podocytes
can induce a neutrophilic burst which is known to be sufficient to trigger a local proinflammatory response [45]. A
direct effect of recombinant CXCL13 on neutrophils could
be excluded, as after 8 h free CXCL13 was no longer detectable in the culture medium (data not shown); this also indicates indirectly that CXCL13 is bound or absorbed by the
cultured podocytes.
Taken together, our results provide further evidence that
CXCL13 is involved in the pathogenesis of lupus nephritis
and that podocytes play an active role in immunological
mechanisms after CXCL13 stimulation. Thus, CXCL13
blockade may be an effective therapy for different types of
podocyte-related kidney diseases in general and for lupus
nephritis in particular.
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